"The board of directors determined the plan was a reasonable form of protection for shareholders during a period of an artificially low share price," said Yacha Sutton, CEO. He added that the plan does not prevent a fairly valued bid for the company.
Lumenis develops laser and light-based technologies for medical and aesthetic applications.